Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) was $8.97 for the day, up 1.59% from the previous closing price of $8.83. In other words, the price has increased by $1.59 from its previous closing price. On the day, 3.46 million shares were traded.
Ratios:
Our analysis of PHAT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.54 and its Current Ratio is at 3.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23.
Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 21 ’25 when Topper James N bought 3,780 shares for $3.86 per share. The transaction valued at 14,609 led to the insider holds 59,403 shares of the business.
Topper James N bought 6,300 shares of PHAT for $20,919 on May 14 ’25. The Director now owns 55,623 shares after completing the transaction at $3.32 per share. On May 13 ’25, another insider, Topper James N, who serves as the Director of the company, bought 1,120 shares for $3.16 each. As a result, the insider paid 3,543 and bolstered with 49,323 shares of the company.
Stock Price History:
Over the past 52 weeks, PHAT has reached a high of $19.71, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 104.37%, while the 200-Day Moving Average is calculated to be -2.29%.
Shares Statistics:
A total of 69.64M shares are outstanding, with a floating share count of 37.85M. Insiders hold about 45.79% of the company’s shares, while institutions hold 47.84% stake in the company.
Earnings Estimates
A comprehensive evaluation of Phathom Pharmaceuticals Inc (PHAT) is underway, with the input of 4.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.55, with high estimates of -$0.34 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$2.45 and -$3.36 for the fiscal current year, implying an average EPS of -$2.9. EPS for the following year is -$0.47, with 5.0 analysts recommending between $0.34 and -$2.32.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $37M to a low estimate of $32.7M. As of the current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $7.32MFor the next quarter, 7 analysts are estimating revenue of $42.62M. There is a high estimate of $47.37M for the next quarter, whereas the lowest estimate is $37.4M.
A total of 8 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $172.6M, while the lowest revenue estimate was $146.9M, resulting in an average revenue estimate of $159.6M. In the same quarter a year ago, actual revenue was $55.25MBased on 8 analysts’ estimates, the company’s revenue will be $328.54M in the next fiscal year. The high estimate is $381.1M and the low estimate is $270M.
